Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- Japan Govt OKs Basic Policy for FY2014 Budget; Wording Tweaked in Favor of Healthcare Circles
December 17, 2013
- Diovan Panel to Reopen Discussions on Dec. 25, Hear from 3 Universities
December 17, 2013
- Amount of Funding from Pharma Companies to Healthcare Professionals Totals 466.6 Billion Yen in FY2012
December 17, 2013
- Bill Payers at Chuikyo Oppose Proposal on Evaluation of Generic Drug Use at DPC Hospitals; Subcommittee to Meet Again on Dec. 18
December 16, 2013
- First Generics of Livalo, Glivec Added to NHI Price List: MHLW
December 13, 2013
- No Diovan, Livalo AGs for December Generic NHI Listing
December 13, 2013
- PFSB Begins Discussions Toward Lifting Ban on Subcontracting of Safety Management Tasks
December 12, 2013
- MHLW Notifies Authorities of Expiration Date Extension for Relenza from 7 to 10 Years
December 12, 2013
- 3-Drug Therapy Including Simeprevir for Chronic Hepatitis C to Be Eligible for Medical Expense Assistance: MHLW
December 11, 2013
- September Price Settlement Rate at 73.5%; Low Figure Blamed on Pharmacy Chains
December 10, 2013
- Japan Diet Enacts Bill to Open Door for Online OTC Drug Sales
December 10, 2013
- FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition
December 9, 2013
- Average Drug Price Discrepancy Rate at 8.2%: Health Ministry
December 9, 2013
- PMDA Aims to Solidify Partnerships with Overseas Regulators via February Symposium
December 9, 2013
- MHLW to Make Additional Appeal for Applicants for Special Grants to Produce Vaccines for New Strains of Influenza
December 6, 2013
- MHLW Calls for Caution on ADRs Associated with Axitinib, Bevacizumab
December 6, 2013
- Revision of Notification on Advanced Healthcare Introduces New Rules for Anticancer Drugs
December 5, 2013
- Would Proposed New Rule for Repricing Long-Listed Drugs Create Winners and Losers? Bill Payers Opposed, Industry Watching Closely
December 5, 2013
- PAFSC’s First Committee Backs Japan’s 1st SGLT-2 Inhibitor
December 2, 2013
- 11 APIs/33 Products Including ComPlavin Added to NHI Price List
December 2, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…